<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01860105</url>
  </required_header>
  <id_info>
    <org_study_id>MDCO-157-12-01</org_study_id>
    <nct_id>NCT01860105</nct_id>
  </id_info>
  <brief_title>Appraisal of MDCO-157 and Plavix® Pharmacokinetics and Pharmacodynamics in Healthy Volunteers With an Evaluation</brief_title>
  <acronym>AMPHORE</acronym>
  <official_title>Appraisal of MDCO-157 and Plavix® Pharmacokinetics and Pharmacodynamics in Healthy Volunteers With an Open-label, Randomized, Cross-over Evaluation: The AMPHORE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Medicines Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Medicines Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following a first, dose ascending study that enrolled 144 normal healthy volunteers (NHVs),&#xD;
      this study, to be conducted in approximately 36 NHVs, will provide pertinent information in&#xD;
      determining the dose-response of MDCO-157 for platelet aggregation inhibition and P2Y12&#xD;
      receptor inhibition effects and in selection of doses that match the antiplatelet effects of&#xD;
      300 mg PLAVIX® ®. The study will also provide additional data for pharmacokinetics (PK),&#xD;
      safety and tolerability of single doses of MDCO-157.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Response of MDCO-157 (3 doses) compared to Plavix 300 mg</measure>
    <time_frame>24 hr</time_frame>
    <description>To evaluate the dose-response of MDCO-157 (at 3 doses) compared to Plavix (300 mg), using Emax and AUEC with VASP, over 24 hours:&#xD;
Maximum effect of P2Y12 receptor inhibition (Emax) using VASP (flow cytometry)&#xD;
Area under the effect of P2Y12 receptor inhibition time curve (AUEC) using VASP (flow cytometry)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of MDCO-157 and its metabolites</measure>
    <time_frame>24 hrs</time_frame>
    <description>To determine the pharmacokinetic (PK) of MDCO-157, including clopidogrel, clopidogrel carboxylic acid, and clopidogrel H4 thiol active metabolite in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>48 hrs post each treatment period</time_frame>
    <description>To assess the safety and tolerability of single doses of MDCO 157 (75 mg, 150mg and 300mg) as measured by assessment of AEs and SAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose response of MDCO-157 as assessed by LTA</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose response of MDCO-157 as assess by VerifyNow P2Y12 assay</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Pharmacokinetics and Pharmacodynamics in Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>75mg MDCO-157</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150mg MDCO-157</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300mg MDCO-157</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300mg PLAVIX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDCO-157</intervention_name>
    <description>intravenous administration</description>
    <arm_group_label>150mg MDCO-157</arm_group_label>
    <arm_group_label>300mg MDCO-157</arm_group_label>
    <arm_group_label>75mg MDCO-157</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLAVIX</intervention_name>
    <description>oral administration</description>
    <arm_group_label>300mg PLAVIX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Healthy males or females 18 to 45 years of age, inclusive.&#xD;
&#xD;
          -  Provide written informed consent for genetic testing and written informed consent for&#xD;
             the study before initiation of any study related procedures&#xD;
&#xD;
          -  Affiliated to the French social security system&#xD;
&#xD;
          -  Screening and baseline Fridericia's correction (QTcF) interval &lt; 450 msec and baseline&#xD;
             heart rate between 50 and 100 bpm (inclusive)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected hypersensitivity or allergy to clopidogrel, Captisol, PLAVIX® , or&#xD;
             its excipients&#xD;
&#xD;
          -  Body mass index &lt;20 or &gt; 30 kg/m²&#xD;
&#xD;
          -  Inability to communicate with the investigator or comply with study related&#xD;
             procedures, or high likelihood of being lost to follow up&#xD;
&#xD;
          -  Known or suspected pregnancy or lactating female&#xD;
&#xD;
          -  Medical history, physical examination including 12-lead ECG or laboratory evaluation&#xD;
             conducted at the screening visit with results indicative of any disease or condition&#xD;
             which might compromise the hematologic, cardiovascular, pulmonary, renal,&#xD;
             gastrointestinal, hepatic, or central nervous system; or other conditions that may&#xD;
             interfere with the absorption, distribution, metabolism or excretion of study drug, or&#xD;
             would place the subject at increased risk&#xD;
&#xD;
          -  Tobacco product use within the last 6 months prior to dosing&#xD;
&#xD;
          -  Platelet count &lt; 150,000/µL&#xD;
&#xD;
          -  A personal or family history of coagulation or bleeding disorders or reasonable&#xD;
             suspicion of vascular malformations&#xD;
&#xD;
          -  Active pathological bleeding such as peptic ulcer or intracranial hemorrhage&#xD;
&#xD;
          -  Positive screen for Hepatitis B (Hepatitis B Surface Antigen HBsAg), Hepatitis C&#xD;
             (Hepatitis C Antibody), or HIV (anti-HIV 1/2)&#xD;
&#xD;
          -  Received an investigational drug within a period of 30 days or 5 half-lives, whichever&#xD;
             is longer, prior to enrollment in the study&#xD;
&#xD;
          -  Use of aspirin, other non-steroidal anti-inflammatory drugs, CYP3A4 inhibitors&#xD;
             (ketoconazole), CYP2C19 inhibitors (eg, omeprazole) or other drugs known to affect&#xD;
             platelet function or coagulation within 14 days prior to receiving study drug&#xD;
             (MDCO-157 or oral clopidogrel)&#xD;
&#xD;
          -  Grapefruit within 10 days prior to receiving study drug (MDCO-157 or PLAVIX®)&#xD;
&#xD;
          -  Use of any over-the-counter medication, including herbal products, within 7 days prior&#xD;
             to administration of study drug (MDCO-157 or PLAVIX®), except for up to 2 grams of&#xD;
             acetaminophen per day for up to 3 days for pain control&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>September 12, 2012</study_first_submitted>
  <study_first_submitted_qc>May 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2013</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

